Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07096362 · ClinicalTrials.gov registry record · Phase 2

Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma

A Phase 2 study of Pancreatic Ductal Adenocarcinoma and Metastatic Pancreatic Ductal Adenocarcinoma, sponsored by University of Miami.

Recruiting
Registry status
Phase 2
Development phase
50
Enrollment target
1
Study location

NCT07096362 is a Phase 2 study of Pancreatic Ductal Adenocarcinoma and Metastatic Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by University of Miami. The registered enrollment target is 50 participants, below the 600-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07096362, a Phase 2 study of Pancreatic Ductal Adenocarcinoma and Metastatic Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by University of Miami.

RECRUITING
Registry status
Phase 2
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to understand whether a blood-based test called circulating tumor DNA (ctDNA) can detect whether participants are having a desired tumor shrinkage or an undesired lack of tumor shrinkage, and to study whether these levels of ctDNA can be used to make treatment decisions faster than the current standard approach, which is to wait 8 weeks after starting chemotherapy to obtain participant first imaging scans since starting chemotherapy.

Conditions Studied

Pancreatic Ductal Adenocarcinoma Metastatic Pancreatic Ductal Adenocarcinoma

Interventions

  • DRUG Leucovorin
  • DRUG Oxaliplatin
  • DRUG Gemcitabine
  • DRUG Irinotecan
  • DRUG 5-Fluorouracil

Study Locations (1)

Florida

  • University of Miami - Miami

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2025-09-09
Est. Completion 2030-09-30
Phase Phase 2

Sponsor

University of Miami

721 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07096362

The ClinicalTrials.gov registry entry for NCT07096362 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 600-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (92% lower). The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Leucovorin is the first listed.

NCT07096362 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT07096362 about?

NCT07096362 is a clinical study titled "Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma". The purpose of this study is to understand whether a blood-based test called circulating tumor DNA (ctDNA) can detect whether participants are having a desired tumor shrinkage or an undesired lack of tumor shrinkage, and to study whether these levels of ctDNA can be used to make treatment decisions ...

What is the current status of trial NCT07096362?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2025-09-09. Estimated completion is 2030-09-30.

What conditions does trial NCT07096362 study?

This clinical trial studies the following conditions: Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma.

What interventions are being tested in trial NCT07096362?

The interventions under investigation include: Leucovorin (DRUG), Oxaliplatin (DRUG), Gemcitabine (DRUG), Irinotecan (DRUG), 5-Fluorouracil (DRUG).

Who is sponsoring clinical trial NCT07096362?

This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07096362 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pancreatic Ductal Adenocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pancreatic Ductal Adenocarcinoma

All registered trials for this condition

Metastatic Pancreatic Ductal Adenocarcinoma

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.